ARTICLE | Company News
Amgen licenses anti-NGF antibody to J&J
August 1, 2008 1:46 AM UTC
Amgen (NASDAQ:AMGN) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights, excluding Japan, to develop and commercialize an undisclosed human anti- nerve growth factor (NGF) antibody. The m...